Subscribe to Newsletter
Diagnostics Clinical care, Oncology, Genetics and epigenetics, Omics

Random Acts of Kinase

Gene fusions – genomic events where parts of two separate genes are connected to form a single hybrid gene – have been found in almost every type of human cancer. With over 10,000 different fusions identified to date (1), it’s unsurprising that they play a role in so many different forms of the disease. In particular, gene fusions involving kinases, such as ALK, RET, ROS1, FGFR, and NTRK, are known to be involved in multiple cancers. The discoveries of those fusions meant new opportunities for patients to receive therapy in clinical trials – but before those treatments could be offered, laboratories needed a clinical-grade test that could detect multiple types of gene fusions, including novel ones. And that’s why Sameek Roychowdhury’s group at the Ohio State Cancer Center developed OSU-SpARKFuse (2) – a new type of gene fusion assay.

“OSU-SpARKFuse involves focused sequencing of tumor RNA through hybridization-based enrichment of a selected panel of transcripts,” explains Roychowdhury. “Because it is not an amplicon-based approach, the assay is not limited to select exons and directionality of gene fusions, and has the capacity to discover fusions involving new gene partners, breakpoints, and orientations.” Why is the test so valuable? Gene fusions can happen in any type of cancer (though they’re more common in certain types, such as thyroid, lung, and cholangiocarcinoma) – which means that the test could hold value for any patient diagnosed with the disease. Currently, a clinical trial at James Cancer Hospital at the Ohio State University offers OSU-SpARKFuse to patients with metastatic or advanced stage cancer of any type.

Such RNA sequencing has value even beyond gene fusions, though. The assay can also detect other transcriptome events, such as splicing or exon skipping. Roychowdhury emphasizes the power of clinical-grade RNA sequencing to detect splicing and gene expression, and to enable immune cell profiling, giving just one example from his own experience: “A young woman with metastatic lung cancer was found to have MET exon skipping and benefited from a MET inhibitor in a clinical trial.”

Receive content, products, events as well as relevant industry updates from The Pathologist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. National Cancer Institute, “Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer” (2017). Available at: Accessed September 15, 2017.
  2. JW Reeser et al., “Validation of a targeted RNA sequencing assay for kinase fusion detection in solid tumors”, J Mol Diagn, 19, 682–696 (2017). PMID: 28802831.
About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Application Notes
Streamlined process of protein purification and evaluation

| Contributed by Shimadzu

LC/MS/MS Method Package for Bile Acids Ver. 2

| Contributed by Shimadzu

Diagnostics Clinical care
Be Sure, Today and Tomorrow—LC-MS in Clinical Research

| Contributed by Thermo Fisher Scientific

Most Popular
Register to The Pathologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Pathologist magazine